Revolution Medicines, Inc. Warrant (RVMDW NASDAQ) stock market data APIs
$0.3967
-0(-0%)
as of November 11, 2025
Try our APIs with
free plan!
Revolution Medicines, Inc. Warrant Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
0.3967
Open
0.3951
High
0.4515
Low
0.3951
52 wk Range
0.0305-0.55
Market Cap
0
Revenue
742 K
Beta
0.989
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines, Inc. Warrant data using free add-ons & libraries
Get Revolution Medicines, Inc. Warrant Fundamental Data
Revolution Medicines, Inc. Warrant Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -1 029 836 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines, Inc. Warrant News
New
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge
Revolution Medicines (RVMD) has been catching attention, with shares moving up 3% in the past day and gaining 28% in the last month. Investors seem curious about what is fueling this change, especiall...
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
This article first appeared on GuruFocus. Cash and Investments: $1.93 billion at the end of Q3 2025. R&D Expenses: $262.5 million for Q3 2025, up from $151.8 million in Q3 2024. G&A Expenses: $52.8 m...
Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment
Earnings Call Insights: Revolution Medicines (RVMD) Q3 2025 MANAGEMENT VIEW * CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing treatment for p...
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
